Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Evolus, Inc.

Get SEC filing alerts via email and in your feed for Evolus, Inc.

EOLS

Evolus, Inc.

About Evolus, Inc.

Evolus, Inc. is a global aesthetic company specializing in non-reimbursed, consumer-pay medical products. Its core offerings include injectable neurotoxins like Jeuveau and hyaluronic acid gels such as Evolysse. Serving aesthetic practitioners and consumers worldwide, the company emphasizes high-quality, minimally invasive treatments, digital marketing, and strategic licensing to drive growth in the expanding medical aesthetics market.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Evolus, Inc.

1
1
Evolus, Inc. Evolus Reports 6.7% Revenue Growth to $73.1 Million in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Evolus, Inc. Evolus Reports $51.6 Million Net Loss Despite 11.6% Revenue Growth in 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Evolus, Inc. Evolus Reports 12.9% Revenue Growth to $68.97 Million in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Evolus, Inc. Evolus Reports 3.7% Revenue Growth to $69.4 Million in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Evolus, Inc. Evolus Reports 15.5% Revenue Growth to $68.5 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Evolus, Inc. Evolus Reports 32% Revenue Growth to $266.3 Million for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Evolus, Inc. Evolus Reports 22% Revenue Growth, Net Loss in Q3 2024 Amid Ongoing Challenges

Via official filing (AI summary) | over 1 year ago | 0 comments